Bernhard Frankenberger
Overview
Explore the profile of Bernhard Frankenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schendel D, Frankenberger B
Oncoimmunology
. 2013 Mar;
2(1):e22410.
PMID: 23483031
The clinical use of lymphocytes engineered to express high affinity T-cell receptors (TCRs) specific for two broadly expressed tumor-associated antigens is strongly limited by MHC-restricted fratricide of lymphocytes and TCR-mediated...
2.
Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, et al.
Mol Med
. 2012 Dec;
18:1499-508.
PMID: 23269976
Our previously reported phase I clinical trial with the allogeneic gene-modified tumor cell line RCC-26/CD80/IL-2 showed that vaccination was well tolerated and feasible in metastatic renal cell carcinoma (RCC) patients....
3.
Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, et al.
J Immunol
. 2012 Jun;
189(2):598-605.
PMID: 22689880
Adoptive transfer of T cells expressing transgenic TCR with antitumor specificity provides a hopeful new therapy for patients with advanced cancer. To fulfill a large need for TCR with high...
4.
Spranger S, Jeremias I, Wilde S, Leisegang M, Starck L, Mosetter B, et al.
Blood
. 2012 Feb;
119(15):3440-9.
PMID: 22371883
The hyaluronan-mediated motility receptor (HMMR/Rhamm) is overexpressed in numerous tumor types, including acute lymphoid leukemia and acute myeloid leukemia (AML). Several studies have reported the existence of T-cell responses directed...
5.
Spranger S, Frankenberger B, Schendel D
J Transl Med
. 2012 Feb;
10:30.
PMID: 22364226
Background: To date very few systems have been described for preclinical investigations of human cellular therapeutics in vivo. However, the ability to carry out comparisons of new cellular vaccines in...
6.
Wege A, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Mannel D, et al.
Int J Cancer
. 2011 May;
129(9):2194-206.
PMID: 21544806
The immunological impact on antibody-based anticancer therapies remains incompletely understood due to the lack of appropriate animal models for in vivo analysis. Here, we present a novel humanized tumor mouse...
7.
Frankenberger B, Schendel D
Eur J Cell Biol
. 2011 Mar;
91(1):53-8.
PMID: 21439674
This review summarizes our studies of the past several years on the development of third generation dendritic cell (DC) vaccines. These developments have implemented two major innovations in DC preparation:...
8.
Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, et al.
J Clin Invest
. 2010 Oct;
120(11):3869-77.
PMID: 20978348
The apoptosis inhibitor protein survivin is overexpressed in many tumors, making it a candidate target molecule for various forms of immunotherapy. To explore survivin as a target antigen for adoptive...
9.
Burdek M, Spranger S, Wilde S, Frankenberger B, Schendel D, Geiger C
J Transl Med
. 2010 Oct;
8:90.
PMID: 20920165
Background: Antigen-loaded dendritic cells (DC) are capable of priming naïve T cells and therefore represent an attractive adjuvant for vaccine development in anti-tumor immunotherapy. Numerous protocols have been described to...
10.
Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S, et al.
J Immunol
. 2010 Jun;
185(1):738-47.
PMID: 20511554
In this paper, we describe a new method for preparation of human dendritic cells (DCs) that secrete bioactive IL-12(p70) using synthetic immunostimulatory compounds as TLR7/8 agonists. Monocyte-derived DCs were generated...